Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2024 | Exploring bacteria strains in cancer therapy

Jan Theys • 14 Sep 2024
ESMO 2024
General

Jan Theys, PhD, Maastricht University, Maastricht, Netherlands, highlights the use of different bacterial strains in cancer therapy, such as facultatively anaerobic bacteria like Salmonella and E. coli, as well as strictly anaerobic strains like Clostridium. Both wild-type and engineered bacteria expressing therapeutic proteins are being tested in preclinical settings and ongoing clinical trials, showing promise in targeted tumor treatment through their interaction with the tumor microenvironment. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Jan Theys

Engineering bacteria to enhance immunotherapy for cancer treatment
0:54
Engineering bacteria to enhance immunotherapy for cancer treatment
Jan Theys • 14 Sep 2024
The intersection of bacterial therapy and immunotherapy in cancer treatment
0:40
The intersection of bacterial therapy and immunotherapy in cancer treatment
Jan Theys • 14 Sep 2024
Engineering bacteria for tumor-targeted therapy using CRISPR-Cas
1:13
Engineering bacteria for tumor-targeted therapy using CRISPR-Cas
Jan Theys • 14 Sep 2024
Navigating regulatory challenges for live bacteria in cancer therapy
2:20
Navigating regulatory challenges for live bacteria in cancer therapy
Jan Theys • 14 Sep 2024

Related Videos

Does toxicity differ between patients treated with SABR for one versus five lesions?
0:39
Does toxicity differ between patients treated with SABR for one versus five lesions?
Robert Olson • 16 May 2026
5-year toxicity following SABR: insights from the SABR-5 trial
0:42
5-year toxicity following SABR: insights from the SABR-5 trial
Robert Olson • 16 May 2026
How should results from the SABR-5 trial guide future SABR studies?
1:05
How should results from the SABR-5 trial guide future SABR studies?
Robert Olson • 16 May 2026
The gut microbiome as a prognostic marker of side effects following radiotherapy
0:45
The gut microbiome as a prognostic marker of side effects following radiotherapy
Miguel Reis Ferreira • 16 May 2026
The content of VJOncology is intended for healthcare professionals